506143293 07/08/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6190024

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
LUDWIG INSTITUTE FOR CANCER RESEARCH	04/25/2006

RECEIVING PARTY DATA

Name:	VEGENICS LIMITED
Street Address:	LEVEL 1, 10 WALLACE AVENUE
City:	TOORAK, VICTORIA
State/Country:	AUSTRALIA
Postal Code:	3142

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	7846437

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3124746300

Email: docket@marshallip.com

Correspondent Name: MARSHALL, GERSTEIN & BORUN LLP

Address Line 1: 233 SOUTH WACKER DRIVE

Address Line 2: SUITE 6300

Address Line 4: CHICAGO, ILLINOIS 60606

ATTORNEY DOCKET NUMBER:	28967/39969B
NAME OF SUBMITTER:	NICK FAIRMAN
SIGNATURE:	/Nick Fairman/
DATE SIGNED:	07/08/2020

Total Attachments: 11

source=Assignment2#page1.tif source=Assignment2#page2.tif source=Assignment2#page3.tif source=Assignment2#page4.tif source=Assignment2#page5.tif

PATENT 506143293 REEL: 053149 FRAME: 0408



PATENT REEL: 053149 FRAME: 0409

ASSIGNMENT OF PATENT AND OTHER INTELLECTUAL PROPERTY RIGHTS

BETWEEN

Ludwig Institute for Cancer Research a Swiss not-for-profit Corporation 601 Third Street New York, New York 10158

AND

Licentia Ltd. Tukholmankatu 8A FI-00290 Helsinki Finland

(collectively ASSIGNOR):

AND

Vegenics Limited Level 1, 10 Wallace Ave Toorak, Victoria 3142 Australia

(ASSIGNEE)

WHEREAS ASSIGNOR is collectively the owner(s) of the entire right, title and interest in the following INTELLECTUAL PROPERTY:

invention(s) or improvement(s) disclosed in applications for Letters Patent of the United States or other countries that are listed in the attached PATENT SCHEDULE; and

said applications listed on the PATENT SCHEDULE, and any and all other applications, both United States and in other countries (including but not limited to WIPO/PCT international applications, European regional or national applications, Australian applications, Canadian applications, and Japanese applications), which ASSIGNOR, the inventors, or other predecessor in interest may file or have filed or be named as applicant(s) or inventor(s), either solely or jointly with others, on said invention or improvements; and

any and all Letters Patent of the United States and other countries, which may be obtained on any of said applications, including but not limited to patents listed

on the PATENT SCHEDULE; and

in any reissue or extension thereof;

WHEREAS ASSIGNOR has agreed (pursuant to the terms of one or more executed written agreements, including a LICENSE AGREEMENT dated 25 April 2006

between Ludwig Institute for Cancer Research, Licentia Ltd., and Vegenics Ltd.) to assign

its entire right, title, and interest in the INTELLECTUAL PROPERTY to Vegenics Limited, Level 1, 10 Wallace Ave, Toorak, 3142 Victoria, Australia (ASSIGNEE) with an effective

date of April 2, 2007;

NOW, THEREFORE, for \$10.00 (Ten Dollars) and other good and valuable

consideration, including consideration defined in other agreement(s) between the parties

(such as the LICENSE AGREEMENT), ASSIGNOR hereby assigns to ASSIGNEE, its

successors and assigns, ASSIGNOR's entire right, title and interest in the

INTELLECTUAL PROPERTY. This assignment is an assignment nunc pro tunc

(retroactively effective) with effective date of April 2, 2007.

This assignment includes the right of ASSIGNOR to apply for and obtain patents

for the INTELLECTUAL PROPERTY; and the rights of ASSIGNOR to bring suit and to claim and retain any damages or other remedies for infringement (including past

infringement) of the INTELLECTUAL PROPERTY.

ASSIGNOR warrants that ASSIGNOR is the owner of the interest herein

assigned; that ASSIGNOR has the right to make this assignment; that the undersigned has

the authority to bind the ASSIGNOR entity whose name appears with the signature of the

undersigned and act on behalf of said ASSIGNOR entity; and that there are no outstanding

prior assignments, licenses (except as recognized in Section 2.5 of the LICENSE

AGREEMENT), or other rights in the interest herein assigned, except in favor of

ASSIGNEE.

Page 2 of 11

ASSIGNOR agrees to provide such further assistance as necessary and reasonably requested by ASSIGNEE, including signing of additional documents, to give effect to this assignment and to facilitate the recordal of ASSIGNEE as owner of the INTELLECTUAL PROPERTY in any jurisdiction and on any relevant register of patent or other intellectual property rights.

WITNESS my hand this 3 day of Decemb, 2007. Edward A. McDermott President Ludwig Institute for Cancer Research a Swiss not-for-profit corporation 601 Third Street New York, New York 10158 WITNESS my hand this 5 day of December, 2007. Acting CEO 2) Marjo Jentron Name: 1240 4 FRNSTROM Licentia Ltd. Tukholmankatu 8A FI-00290 Helsinki Finland WITNESS my hand this 7 day of December, 2007. Controller Licentia Ltd. Tukholmankatu 8A FI-00290 Helsinki

Finland

PATENT SCHEDULE

Pending Applications

MGB Ref.	LUD No.	Country	Application No.	Title	Filing Date
5454	5454.0	CA	2,263,890	Recombinant VEGF-D	8/21/1997
5454	5454.0	JP	5109531/1998	Recombinant VEGF-D	8/21/1997
5454	5454.0	PCT	PCT/US97/14696	Recombinant VEGF-D	8/21/1997
5454A	5454.1	EPO	02018842.1	VEGF-D Growth Factor Antibodies, Vectors and Methods of Use	8/21/1997
N/A	5454.2	EPO	06121918.4	VEGF-D Growth Factor Antibodies, Vectors and Methods of Use	8/21/1997
N/A	5454	HK	00102970.0	VEGF-D Growth Factor Antibodies, Vectors and Methods of Use	8/21/1997
5454F	5454.2	US	10/161,694	VEGF-D Antibodies and Vectors	6/5/2002
5454I	5454.5	US	11/304,585	VEGF-D Growth Factor Antibodies, Vectors and Methods of Use	12/16/2005
5454J	5454.6	US	11/692,774	Growth Factor	3/28/2007
5454K	5454.7	US	11/692,753	Growth Factor	3/28/2007
5454M	5454.8	US	11/772,089	Growth Factor	6/29/2007
5454N	5454.9	US	11/843,367	Growth Factor	8/23/2007
5518	5518	EPO	98966053.5	Expression Vectors and Cell Lines Expression VEGF-D	12/23/1998
5518	5518	HK	01100583.2	Expression Vectors and Cell Lines Expression VEGF-D	12/23/1998
5518	5518	JP	2000526237	Expression Vectors and Cell Lines Expression VEGF-D	12/23/1998
5518	5518	PCT	PCT/US98/27373	Expression Vectors and Cell Lines Expression VEGF-D	12/23/1998
5518A	5518	US	09/219,345	Expression Vectors and Cell Lines Expression VEGF-D	12/23/1998
5563	5563	EPO	99955042.9	Novel Neuropilin/Growth Factor Binding and Uses Thereof	10/19/1999
5563	5563	HK	01106692.7	Novel Neuropilin/Growth Factor Binding and Uses Thereof	10/19/1999
5563	.5563	JP	2000577278	Novel Neuropilin/Growth Factor Binding and Uses Thereof	10/19/1999
5563	5563	PCT	PCT/US99/24430	Novel Neuropilin/Growth Factor Binding and Uses Thereof	10/19/1999
5563C	5563.1	US	10/303,786	Novel Neuropilin/Growth Factor Binding and Uses Thereof	11/26/2002
32133	5496.2	PCT	PCT/FI95/00337	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	6/9/1995
33408	5453.4	CA	2,228,248	Receptor Ligand VEGF-C	8/1/1996
33408A	5453.5	EPO	0501466.0	Receptor Ligand VEGF-C	8/1/1996
33408	5453.4	JP	05071262/97	Receptor Ligand VEGF-C	8/1/1996
33408	5453.4	PCT	PCT/FI96/00427	Receptor Ligand VEGF-C	8/1/1996

Page 4 of 11

MGB Ref.	LUD No.	Country	Application No.	Title	Filing Date
34140	5478.1	EPO	98904842.6	VEGF-C Protein and Gene, Mutants Thereof and Uses Thereof	2/2/1998
34140	5478.1	CA	2,279,554	VEGF-C Protein and Gene, Mutants Thereof and Uses Thereof	2/2/1998
34140	5478.1	JP	0533178/98	VEGF-C Protein and Gene, Mutants Thereof and Uses Thereof	2/2/1998
34140	5478.1	PCT	PCT/US98/01973	VEGF-C Protein and Gene, Mutants Thereof and Uses Thereof	2/2/1998
34140A2	5478.4	US	10/792,461	VEGF-C Protein and Gene, Mutants Thereof and Uses Thereof	3/3/2004
34140A3	5478.5	US	10/792,480	VEGF-C Protein and Gene, Mutants Thereof and Uses Thereof	3/3/2004
34891	5496.4	CA	2,345,276	Flt4 (VEGFR-3) Tumor Imaging and Anti-Tumor Therapy	10/9/1998
34891	5496.4	EPO	99956525.2	Flt4 (VEGFR-3) Tumor Imaging and Anti-Tumor Therapy	10/9/1998
34891	5496.4	JP	2002527404	Flt4 (VEGFR-3) Tumor Imaging and Anti-Tumor Therapy	10/9/1998
34891	5496.4	PCT	PCT/US99/23525	Flt4 (VEGFR-3) Tumor Imaging and Anti-Tumor Therapy	10/8/1999
34891.1	5496.5	AU	2004208675	Flt4 (VEGFR-3) Tumor Imaging and Anti-Tumor Therapy	10/9/1998
34891.1	5496.5	US	10/774,802	Flt4 (VEGFR-3) Tumor Imaging and Anti-Tumor Therapy	02/09/2004
34891A	5705	AU	2002248372	Flt4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy	1/22/2002
34891A	5705	CA	2,435,503	Flt4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy	1/22/2002
34891A	5705	JP	20044532004	Flt4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy	1/22/2002
34891A	5705	PCT	PCT/US02/01784	Flt4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy	1/22/2002
34891A2	5705.1	US	11/327,075	Flt4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy	1/6/2006
35061A2	5581.2	US	11/064,769	Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis	2/24/2005
35977B2	5635.2	AU	2006235995	Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins and Screening Methods for Modulators	2/26/2001
35977B	5635.1	CA	2,400,948	Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins and Screening Methods for Modulators	2/26/2001

MGB Ref.	LUD No.	Country	Application No.	Title	Filing Date
35977B	5635.1	EPO	01914501.0	Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins and Screening Methods for Modulators	2/26/2001
35977B	5635.1	JP	2004507208	Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins and Screening Methods for Modulators	2/26/2001
35977B	5635.1	PCT	PCT/US01/06113	Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins and Screening Methods for Modulators	2/26/2001
35977B2	5635.2	US	11/064,774	Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins and Screening Methods for Modulators	2/24/2005
35977B3	5635.3	US	11/846,337	Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins and Screening Methods for Modulators	8/28/2007
37084A	5702	AU	2002225265	VEGFR-3 Binding Peptides and Their Use for Inhibiting Angiogenesis	1/16/2002
37084A	5702	CA	2,450,929	VEGFR-3 Binding Peptides and Their Use for Inhibiting Angiogenesis	1/16/2002
37084A	5702	EPO	02715608.2	VEGFR-3 Binding Peptides and Their Use for Inhibiting Angiogenesis	1/16/2002
37084A	5702	PCT	PCT/IB02/00099	VEGFR-3 Binding Peptides and Their Use for Inhibiting Angiogenesis	1/16/2002
37084A	5702	US	10/046,922	VEGFR-3 Binding Peptides and Their Use for Inhibiting Angiogenesis	1/15/2002
37521B	5732.2	AU	2002322461	Lymphatic Endothelial Cells Materials and Methods	7/12/2002
37521B	5732.2	CA	2,453,161	Lymphatic Endothelial Cells Materials and Methods	7/12/2002
37521B	5732.2	EPO	027564533	Lymphatic Endothelial Cells Materials and Methods	7/12/2002
37521B	5732.2	JP	2005500045	Lymphatic Endothelial Cells Materials and Methods	7/12/2002
37521A	5732.2	PCT	PCT/US02/22164	Lymphatic Endothelial Cells Materials and Methods	7/12/2002
37521B	5732.2	US	10/483,203	Lymphatic Endothelial Cells Materials and Methods	7/12/2002
37564A	5731.1	AU	2002329287	Neuropilin/VEGF-C/VEGFR-3 Materials and Methods	10/1/2002
37564A	5731.1	CA	2,462,672	Neuropilin/VEGF-C/VEGFR-3 Materials and Methods	10/1/2002

MGB Ref.	LUD No.	Country	Application No.	Title	Filing Date
37564A	5731.1	EPO	02764893.0	Neuropilin/VEGF-C/VEGFR-3 Materials and Methods	10/1/2002
37564A	5731.1	HK	04109217.4	Neuropilin/VEGF-C/VEGFR-3 Materials and Methods	10/1/2002
37564A	5731.1	PCT	PCT/EP02/11069	Neuropilin/VEGF-C/VEGFR-3 Materials and Methods	10/1/2002
37564A	5731.1	US	10/262,538	Neuropilin/VEGF-C/VEGFR-3 Materials and Methods	09/30/2002
37564C	5731.5	US	11/600,479	Neuropilin/VEGF-C/VEGFR-3 Materials and Methods	11/16/2006
38632	5777	US	10/326,048	Modulation of VEGF-C/VEGFR-3 Interactions in the Treatment of Rheumatoid Arthritis	12/20/2002
39117A	5813.0	EPO	04776654.8	Use of VEGF-C or VEGF-D in Reconstructive Surgery	6/14/2004
39117A	5813.0	PCT	PCT/US04/019197	Use of VEGF-C or VEGF-D in Reconstructive Surgery	06/14/2004
39117A	5813.0	US	10/868,549	Use of VEGF-C or VEGF-D in Reconstructive Surgery	6/14/2004
39117B	5813.1	US	11/782,225	Use of VEGF-C or VEGF-D in Reconstructive Surgery	7/24/2007
39178	5778	US	10/505,928	Lymphatic and Blood Endothelial Cell Genes	03/7/2003
39230A	5846	PCT	PCT/US04/29245	Lymphatic and Blood Endothelial Cell Genes	09/08/2004
39230A	5846	US	10/570,963	Lymphatic and Blood Endothelial Cell Genes	09/08/2004
39359A	5849	PCT	PCT/US04/19122	Heparin Binding VEGFR-3 Ligands	06/14/2004
39359A	5849.1	US	10/868,577	Heparin Binding VEGFR-3 Ligands	06/12/2003
39700A	5874.1	AU	2005222384	Growth factor binding Materials and Methods	03/7/2005
39700A	5874.1	EPO	05725099.5	Growth factor binding Materials and Methods	03/7/2005
39700A	5874.1	PCT	PCT/US05/07741	Growth factor binding Materials and Methods	03/7/2005
39700A	5874.1	US	11/075,047	Growth factor binding Materials and Methods	03/7/2005
39820B	5890.2	EPO	05731973.3	Multivalent Antibody Materials and Methods for VEGF/PDGF Family of Growth Factors	03/7/2005
39820B	5890.2	PCT	PCT/US05/07742	Multivalent Antibody Materials and Methods for VEGF/PDGF Family of Growth Factors	03/7/2005
39820B	5890.2	US	11/075,400	Multivalent Antibody Materials and Methods for VEGF/PDGF Family of Growth Factors	03/7/2005

MGB Ref.	LUD No.	Country	Application No.	Title	Filing Date
39969A	5878.1	PCT	PCT/US05/07283	Chimeric Anti VEGF-D Antibodies and Humanized Anti-VEGF-D Antibodies and Methods of Using Same	03/7/2005
39969A	5878.1	US	11/074,373	Chimeric Anti VEGF-D Antibodies and Humanized Anti-VEGF-D Antibodies and Methods of Using Same	03/7/2005
40008A	5896.1	PCT	PCT/US05/07693	Compositions and Methods for Treatment of Lymphatic Vascularization	03/08/2005
40008A	5896.1	US	11/076,427	Compositions and Methods for Treatment of Lymphatic Vascularization	03/08/2005
41018A	5939.1	PCT	PCT/US06/32012	Modified VEGF-A with Improved Angiogenic Properties	08/15/2006
41018A	5939.1	US	11/505,100	Modified VEGF-A with Improved Angiogenic Properties	08/15/2006

Issued Patents

MGB Ref.	LUD No.	Country	Patent No.	Title	Issue Date
5454	5454.0	AT	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	AU	729880	Recombinant VEGF-D	2/15/2001
5454	5454.0	BE	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	CH/LI	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	DE	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	DK	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	EPO	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	ES	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	FI	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	FR	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	GB	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	GR	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	IE	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	IT	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	LU	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	NL	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	PT	956339	Recombinant VEGF-D	10/12/2005
5454	5454.0	SE	956339	Recombinant VEGF-D	10/12/2005
5454D	5454.0	US	6,235,713	VEGF-D Polypeptides	5/22/2001
5454E	5454.1	US	6,689,580	VEGF-D Polypeptides	2/10/2004
5454G	5454.3	US	7,122,654	VEGF-D Polypeptides	10/7/2006
5518	5518	AU	765888	Expression Vectors and Cell Lines Expression VEGF-D	10/2/2003
5518	5518	KR	10-0628697	Expression Vectors and Cell Lines Expression VEGF-D	9/20/2006

Page 8 of 11

MGB Ref.	LUD No.	Country	Patent No.	Title	Issue Date
5563	5563	AU	780593	Novel Neuropilin/Growth Factor Binding and Uses Thereof	4/7/2005
5563B	5563	US	6,515,105	Novel Neuropilin/Growth Factor Binding and Uses Thereof	2/4/2003
32133	5496.2	AT	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	BE	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	СН	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	DE	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	DK	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	EPO	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	ES	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	FI	964862	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	02/10/1997
32133	5496.2	FR	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	GB	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	GR	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	IE .	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	IT	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	JP	03723210	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	12/7/2005
32133	5496.2	LU	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	MC	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	NL	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	PT	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32133	5496.2	SE	807124	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	05/17/2006
32267	5496.0	US	5,776,755	Flt4 Receptor Tyrosine Kinase and Its Use in Diagnosis and Therapy	7/7/1998
32863	5453	US	6,221,839	FLT4 Ligand and Methods of Use	4/24/2001
33072	5453.1	US	6,245,530	Receptor Ligand VEGF-C	6/12/20

MGB Ref.	LUD No.	Country	Patent No.	Title	Issue Date
33118	5453.2	US	6,403,088	Antibodies Reactive with VEGF-C, A Ligand for the FLT4 Receptor Tyrosine Kinase	6/11/2002
33348A	5453.5	US	6,730,658	Stimulation of Lymphatic Growth with an FLT4 Ligand	5/4/2004
33408	5453.3	US	6,645,933	Receptor Ligand VEGF-C	11/11/2003
33408	5453.4	AT	0290594	Receptor Ligand VEGF-C	3/15/2005
33408	5453.4	AU	711758	Receptor Ligand VEGF-C	10/14/1999
33408	5453.4	BE	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	СН	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	DE	69634437	Receptor Ligand VEGF-C	4/18/2005
33408	5453.4	DK	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	EPO	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	ES	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	FI	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	FR	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	GB	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	GR	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	IE	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	IT	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	LU	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	MC	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	NL	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	PT	842273	Receptor Ligand VEGF-C	3/9/2005
33408	5453.4	SE	842273	Receptor Ligand VEGF-C	3/9/2005
33408A	5453.5	AU	755708	Receptor Ligand VEGF-C	12/19/2002
33408B	5453.6	AU	2003201371	Receptor Ligand VEGF-C	????
33691	5478	US	6,130,071	Vascular endothelial Growth Factor C	10/10/2000
	J476		0,130,071	(VEGF-C) ΔCys ₁₅₆ Protein and Gene	10/10/2000
		ļ	- 10= 0.1c	and Uses Thereof	2/22/2000
33824	5496.3	US	6,107,046	Antibodies to Flt4 Receptor Tyrosine	8/22/2000
				Kinase and Uses Thereof	2/20/2002
34140	5478.1	AU	748369	VEGF-C Protein and Gene, Mutants	3/20/2003
			5.044.045	Thereof and Uses Thereof	02/06/2002
34140	5478.1	US	6,361,946	VEGF-C Protein and Gene, Mutants Thereof and Uses Thereof	03/26/2002
34140A	5478.2	AU	2002300880	VEGF-C Protein and Gene, Mutants	06/23/2006
				Thereof and Uses Thereof	
34140A	5478.2	US	6,818,220	VEGF-C Protein and Gene, Mutants	11/16/2004
34140B	5.470.0	110	7.105.714	Thereof and Uses Thereof	10/24/2006
	5478.3	US	7,125,714	Progenitor Cell Materials and Methods	10/24/2000
2/1901	5496.4	AU	774266	Flt4 (VEGFR-3) Tumor Imaging and	06/15/2006
34891	3470.4	AU	114400	Anti-Tumor Therapy	30/15/2000

MGB Ref.	LUD No.	Country	Patent No.	Title	Issue Date
34891	5496.4	US	6,824,777	Flt4 (VEGFR-3) Tumor Imaging and Anti-Tumor Therapy	11/30/2004
34891A	5705	CH/LI	1353592	FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor therapy	4/11/2007
34891A	5705	DE	1353592	FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor therapy	4/11/2007
34891A	5705	ЕР	1353592	FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor therapy	4/11/2007
34891A	5705	FR	1353592	FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor therapy	4/11/2007
34891A	5705	GB	1353592	FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor therapy	4/11/2007
34891A	5705	IT	1353592	FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor therapy	4/11/2007
34891A	5705.0	US	7,034,105	Flt4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy	4/25/2006
35977B	5635.1	AU	2001239884	Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins and Screening Methods for Modulators	11/23/2006
35977В	5635.1	US	6,965,010	Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins and Screening Methods for Modulators.	11/15/2005

Page 11 of 11

RECORDED: 07/08/2020